Mike HoneyHere's the latest variant picture for the United Kingdom, to mid-February.
BA.3.2.* "Cicada" continued to dominate at 72%.
XFG.* "Stratus" continued falling to finish at 25%
Recent samples are only from Northern Ireland.
Here's the latest variant picture for the United Kingdom, to early February.
BA.3.2.* "Cicada" continued its sharp grew suddenly and took over dominance at 44%.
XFG.* "Stratus" continued falling to finish at 32%
Here's the latest variant picture for the United Kingdom, to late January.
XFG.* "Stratus" continued falling sharply to finish at 38%
BA.3.2.* grew suddenly and is challenging for dominance at 34%.
Here's the latest variant picture for the United Kingdom, to mid-January.
XFG.* "Stratus" remained dominant, but fell sharply to 44%
NB.1.8.1.* "Nimbus" grew steadily to 31%.
BA.3.2.* fell slightly to 20%.
This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
Here's the latest variant picture for Europe (excluding the UK), to early January.
BA.3.2.* "Cicada" showed a steady growth advantage of 7% per day (49% per week) over XFG.* "Stratus", with a crossover in late December.
Here's the latest variant picture for the United Kingdom, to early January.
BA.3.2.* soared to 70% of recent samples in Scotland.
Here's the latest variant picture for Australia, to early January.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* "Cicada", NB.1.8.1.* "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" all finished in the 22-26% range. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
Here's the latest variant picture with a global scope, to early January.
Globally from November, BA.3.2.* "Cicada" showed a growth advantage of 3.5% per day (25% per week) over XFG.* "Stratus". Recent volumes have been dominated by the US and Canada, where XFG.* is still dominant.
Here's the latest variant picture for Australia, to late December.
The overall view is muddied by patchy sequencing volumes. BA.3.2.* finished at 27% with NB.1.8.1.* "Nimbus" just higher at 35%.
In a chaotic scene, JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" are also significant. This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.
Here's the latest variant picture with a global scope, to late December.
Globally BA.3.2.* "Cicada" showed a growth advantage of 5% per day (36% per week) over XFG.* "Stratus". The low sample sizes reported for late-December make this even more uncertain than usual.
